VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q116785435 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241221010637.0
008 241221nneanz||abbn n and d
035 ‎‡a (WKP)Q116785435‏
035 ‎‡a (OCoLC)Q116785435‏
100 0 ‎‡a Tse-I Lin‏ ‎‡c researcher‏ ‎‡9 en‏
670 ‎‡a Author's 1,5-Benzodiazepine inhibitors of HCV NS5B polymerase‏
670 ‎‡a Author's 2'-Deoxy-2'-spirocyclopropylcytidine revisited: a new and selective inhibitor of the hepatitis C virus NS5B polymerase‏
670 ‎‡a Author's Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase‏
670 ‎‡a Author's Discovery of 1-((2R,4aR,6R,7R,7aR)-2-Isopropoxy-2-oxidodihydro-4H,6H-spiro[furo[3,2-d][1,3,2]dioxaphosphinine-7,2'-oxetan]-6-yl)pyrimidine-2,4(1H,3H)-dione (JNJ-54257099), a 3'-5'-Cyclic Phosphate Ester Prodrug of 2'-Deoxy-2'-Spirooxetane Uridine Tr‏
670 ‎‡a Author's Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors.‏
670 ‎‡a Author's Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors‏
670 ‎‡a Author's Finger-loop inhibitors of the HCV NS5b polymerase. Part 1: Discovery and optimization of novel 1,6- and 2,6-macrocyclic indole series‏
670 ‎‡a Author's Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055.‏
670 ‎‡a Author's In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor‏
670 ‎‡a Author's Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target‏
670 ‎‡a Author's Structure-based macrocyclization yields hepatitis C virus NS5B inhibitors with improved binding affinities and pharmacokinetic properties‏
670 ‎‡a Author's Synthesis and SAR of potent inhibitors of the Hepatitis C virus NS3/4A protease: exploration of P2 quinazoline substituents‏
670 ‎‡a Author's TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage‏
919 ‎‡a 2deoxy2spirocyclopropylcytidinerevisitedanewandselectiveinhibitorofthehepatitis100virusns5bpolymerase‏ ‎‡A 2'-Deoxy-2'-spirocyclopropylcytidine revisited: a new and selective inhibitor of the hepatitis C virus NS5B polymerase‏ ‎‡9 1‏
919 ‎‡a discoveryandearlydevelopmentoftmc647055anonnucleosideinhibitorofthehepatitis100virusns5bpolymerase‏ ‎‡A Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase‏ ‎‡9 1‏
919 ‎‡a tmc647055apotentnonnucleosidehepatitis100virusns5bpolymeraseinhibitorwithcrossgenotypiccoverage‏ ‎‡A TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage‏ ‎‡9 1‏
919 ‎‡a synthesisandsarofpotentinhibitorsofthehepatitis100virusns34aproteaseexplorationofp2quinazolinesubstituents‏ ‎‡A Synthesis and SAR of potent inhibitors of the Hepatitis C virus NS3/4A protease: exploration of P2 quinazoline substituents‏ ‎‡9 1‏
919 ‎‡a 15benzodiazepineinhibitorsofhcvns5bpolymerase‏ ‎‡A 1,5-Benzodiazepine inhibitors of HCV NS5B polymerase‏ ‎‡9 1‏
919 ‎‡a structurebasedmacrocyclizationyieldshepatitis100virusns5binhibitorswithimprovedbindingaffinitiesandpharmacokineticproperties‏ ‎‡A Structure-based macrocyclization yields hepatitis C virus NS5B inhibitors with improved binding affinities and pharmacokinetic properties‏ ‎‡9 1‏
919 ‎‡a inducedfitbindingofthemacrocyclicnoncovalentinhibitortmc435toitshcvns3ns4aproteasetarget‏ ‎‡A Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target‏ ‎‡9 1‏
919 ‎‡a invitroactivityandpreclinicalprofileoftmc435350apotenthepatitis100virusproteaseinhibitor‏ ‎‡A In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor‏ ‎‡9 1‏
919 ‎‡a fingerloopinhibitorsofthehcvns5bpolymerasepart2optimizationoftetracyclicindolebasedmacrocycleleadingtothediscoveryoftmc647055‏ ‎‡A Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055.‏ ‎‡9 1‏
919 ‎‡a fingerloopinhibitorsofthehcvns5bpolymerasepart1discoveryandoptimizationofnovel16and26macrocyclicindoleseries‏ ‎‡A Finger-loop inhibitors of the HCV NS5b polymerase. Part 1: Discovery and optimization of novel 1,6- and 2,6-macrocyclic indole series‏ ‎‡9 1‏
919 ‎‡a evaluationoftheantihepatitis100viruseffectofnovelpotentselectiveandorallybioavailablejnkandvegfrkinaseinhibitors‏ ‎‡A Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors‏ ‎‡9 1‏
919 ‎‡a discoveryofnovelpotentandbioavailableprolineureabasedmacrocyclichcvns34aproteaseinhibitors‏ ‎‡A Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors.‏ ‎‡9 1‏
919 ‎‡a discoveryof12r4ar6r7r7ar2isopropoxy2oxidodihydro4h6hspiro6ylpyrimidine241h3hdionejnj54257099a35cyclicphosphateesterprodrugof2deoxy2spirooxetaneuridinetr‏ ‎‡A Discovery of 1-((2R,4aR,6R,7R,7aR)-2-Isopropoxy-2-oxidodihydro-4H,6H-spiro[furo[3,2-d][1,3,2]dioxaphosphinine-7,2'-oxetan]-6-yl)pyrimidine-2,4(1H,3H)-dione (JNJ-54257099), a 3'-5'-Cyclic Phosphate Ester Prodrug of 2'-Deoxy-2'-Spirooxetane Uridine Tr‏ ‎‡9 1‏
996 ‎‡2 ISNI|000000005144899X‏
996 ‎‡2 J9U|987007386512905171‏
996 ‎‡2 ISNI|0000000076034080‏
996 ‎‡2 LC|n 82051132‏
996 ‎‡2 DNB|118980327‏
996 ‎‡2 NDL|00470510‏
996 ‎‡2 NLA|000036690241‏
996 ‎‡2 ISNI|0000000063272047‏
996 ‎‡2 ISNI|0000000063484162‏
996 ‎‡2 SUDOC|112997392‏
996 ‎‡2 NTA|304357936‏
996 ‎‡2 CYT|AC000614682‏
996 ‎‡2 LC|n 00004576‏
996 ‎‡2 ISNI|0000000064045225‏
996 ‎‡2 ISNI|0000000064357966‏
996 ‎‡2 CAOONL|ncf11484697‏
996 ‎‡2 J9U|987007386291605171‏
996 ‎‡2 NLA|000036724775‏
996 ‎‡2 NTA|127744622‏
996 ‎‡2 ISNI|0000000027964062‏
996 ‎‡2 NLA|000036596450‏
996 ‎‡2 LC|no2008184695‏
996 ‎‡2 NLA|000036679858‏
996 ‎‡2 LC|n 82075582‏
996 ‎‡2 NII|DA03718809‏
996 ‎‡2 BNE|XX1129775‏
996 ‎‡2 LC|no 98076155‏
996 ‎‡2 NLA|000036623831‏
996 ‎‡2 LC|n 94056437‏
996 ‎‡2 DNB|1089442270‏
996 ‎‡2 LC|n 84165298‏
996 ‎‡2 NLA|000036679748‏
996 ‎‡2 NII|DA07171442‏
996 ‎‡2 NLA|000036696122‏
996 ‎‡2 RERO|A021644162‏
996 ‎‡2 ISNI|0000000377839923‏
996 ‎‡2 CYT|AC000222698‏
996 ‎‡2 NTA|140571094‏
996 ‎‡2 NTA|155947060‏
996 ‎‡2 NLA|000036621447‏
996 ‎‡2 LC|no2018073387‏
996 ‎‡2 BIBSYS|90306703‏
996 ‎‡2 ISNI|000000006420103X‏
996 ‎‡2 LC|no2010076681‏
996 ‎‡2 NLA|000036625972‏
996 ‎‡2 NLA|000036714410‏
996 ‎‡2 NLA|000036653307‏
996 ‎‡2 ISNI|000000044459869X‏
996 ‎‡2 ISNI|0000000063523520‏
996 ‎‡2 NLA|000036611732‏
996 ‎‡2 PLWABN|9810549898705606‏
996 ‎‡2 CAOONL|ncf10356479‏
996 ‎‡2 CYT|AC000207774‏
996 ‎‡2 BIBSYS|90375110‏
996 ‎‡2 NLA|000036610918‏
996 ‎‡2 NLA|000036602974‏
996 ‎‡2 LC|n 87920569‏
996 ‎‡2 BIBSYS|90211815‏
996 ‎‡2 ISNI|000000008378375X‏
996 ‎‡2 ISNI|000000008315278X‏
996 ‎‡2 LC|n 84032080‏
996 ‎‡2 SUDOC|185952372‏
996 ‎‡2 J9U|987007264495705171‏
996 ‎‡2 ISNI|0000000063495419‏
996 ‎‡2 LC|no2008104419‏
996 ‎‡2 NLA|000036630272‏
996 ‎‡2 ISNI|0000000079533694‏
996 ‎‡2 CAOONL|ncf10991937‏
996 ‎‡2 ISNI|0000000063446430‏
996 ‎‡2 ISNI|0000000064148152‏
996 ‎‡2 ISNI|0000000063759293‏
996 ‎‡2 SUDOC|074766279‏
996 ‎‡2 DNB|1035286416‏
996 ‎‡2 CAOONL|ncf10551025‏
996 ‎‡2 ISNI|0000000063988184‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏